Research location
Montclair
California, United States
Advertisement
Research activity in Montclair
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 118 trials and 118 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Montclair
118 linked trials · page 1 of 3Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaNCT07686263 · 2026-08-20 · 1 site observation
RECRUITING
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235 · 2026-07-23 · 1 site observation
RECRUITING
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388 · 2026-06-22 · 1 site observation
RECRUITING
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyNCT07502508 · 2026-04-30 · 1 site observation
RECRUITING
A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaNCT07459647 · 2026-03-31 · 1 site observation
RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23 · 1 site observation
RECRUITING
A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507 · 2026-02-10 · 1 site observation
RECRUITING
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderNCT07115329 · 2026-01-05 · 1 site observation
RECRUITING
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsNCT07502495 · 2026-03-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesNCT07458269 · 2026-03-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653 · 2026-02-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesNCT07284901 · 2026-01-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07281937 · 2025-11-25 · 1 site observation
COMPLETED
Taldefgrobep Alfa in Adults With Overweight and ObesityNCT07281495 · 2025-11-24 · 1 site observation
ACTIVE_NOT_RECRUITING
GV101 in Healthy Obese ParticipantsNCT06979505 · 2025-06-30 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaNCT07038876 · 2025-06-27 · 1 site observation
COMPLETED
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 · 2025-06-23 · 1 site observation
ACTIVE_NOT_RECRUITING
VK2735 for Weight Management Phase 3NCT07104500 · 2025-06-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · 2025-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMNCT06845202 · 2025-03-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaNCT06894212 · 2025-02-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsNCT06737042 · 2025-02-24 · 1 site observation
COMPLETED
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06703021 · 2024-12-20 · 1 site observation
COMPLETED
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · 2024-12-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 · 2024-11-21 · 1 site observation
COMPLETED
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06693843 · 2024-10-28 · 1 site observation
COMPLETED
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseNCT06538116 · 2024-08-26 · 1 site observation
COMPLETED
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and OverNCT06515418 · 2024-06-27 · 1 site observation
TERMINATED
A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled HypertensionNCT06336356 · 2024-06-10 · 1 site observation
COMPLETED
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)NCT06309992 · 2024-04-02 · 1 site observation
COMPLETED
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesNCT06326047 · 2024-03-18 · 1 site observation
COMPLETED
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419 · 2024-03-18 · 1 site observation
COMPLETED
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation
COMPLETED
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver DiseaseNCT05970640 · 2023-08-14 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 · 2023-07-20 · 1 site observation
COMPLETED
Safety and Efficacy Study of S-309309 in Obese AdultsNCT05925114 · 2023-06-21 · 1 site observation
COMPLETED
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · 2023-06-05 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 2023-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenNCT05769608 · 2023-03-13 · 1 site observation
COMPLETED
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-DiabetesNCT05623189 · 2022-12-27 · 1 site observation
COMPLETED
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With ObesityNCT05579977 · 2022-10-27 · 1 site observation
TERMINATED
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaNCT05443724 · 2022-09-01 · 1 site observation
TERMINATED
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With SchizophreniaNCT05463770 · 2022-08-30 · 1 site observation
COMPLETED
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)NCT05731544 · 2022-08-17 · 1 site observation
COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection TherapyNCT05463744 · 2022-08-12 · 1 site observation
COMPLETED
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 DiabetesNCT05433584 · 2022-08-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaNCT05227690 · 2022-06-30 · 1 site observation
COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First TimeNCT05362058 · 2022-06-03 · 1 site observation
COMPLETED
Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 · 2022-03-31 · 1 site observation
COMPLETED
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)NCT05292911 · 2022-03-09 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.